Are We Missing the Issues That Really Matter?

Total Page:16

File Type:pdf, Size:1020Kb

Are We Missing the Issues That Really Matter? A mixed method study on the prevalence, severity and experience of genitourinary symptoms and the impact on sexual function and QoL in postmenopausal women on endocrine therapy for early breast cancer MARIANA S. SOUSA ARE WE MISSING THE ISSUES THAT REALLY MATTER? 1 ARE WE MISSING THE ISSUES THAT REALLY MATTER? A mixed method study on the prevalence, severity and experience of genitourinary symptoms and the impact on sexual function and quality of life in postmenopausal women on endocrine therapy for early breast cancer Mariana de Souza e Sousa A thesis in fulfillment of the requirements for the degree of Doctor of Philosophy Prince of Wales Clinical School Faculty of Medicine University of New South Wales Australia 2015 iii PLEASE TYPE THE UNIVERSITY OF NEW SOUTH WALES Thesis/Dissertation Sheet Surname or Family name: de Souza e Sousa First name: Mariana Other name/s: N/A Abbreviation for degree as given in the University calendar: PhD School: Prince of Wales Clinical School Faculty: Medicine Title: Are we missing the issues that really matter? A mixed-method study on the prevalence, severity and experience of genitourinary symptoms and the impact on sexual function and Qol in postmenopausal women on endocrine therapy for early breast cancer Abstract 350 words maximum: (PLEASE TYPE) The underlying hypothesis of this PhD Is that the negative Impact of adjuvant endocrine therapy on genitourinary symptoms In postmenopausal women with early breast cancer has been underestimated In clinical trials and that there are a myriad of genitourinary symptoms related to or exacerbated by endocrine therapies that are commonly not reported by women to their oncologists. These symptoms can be troublesome and may lead to noncompliance with treatment, especially If associated with other side effects. This Issue has not been comprehensively addressed, resulting In uncertainty regarding the frequency and severity of genitourinary adverse effects associated with antlestrogens and their potential impact on quality of life (QoL). Furthermore, no studies have comprehensively and prospectively evaluated the full range of genitourinary symptoms from before therapy begins and over time. These symptoms include urinary frequency, urgency, Incontinence, dysuria, prolapse among others. This study fills an Important gap In the current literature and Is clinically Important as Interventions could be used to better manage and treat many of these symptoms. A number of data collection methods and Instruments were used In this project, selected on their ability to address the proposed research questions. Using a qualitative approach, with semi-structured Interviews, Study I sought an In-depth Insight of the genitourinary symptoms experienced by women with early breast cancer on antlestrogen therapy and an understanding on how symptoms Impact on dally life and sexual function. Study II employed a prospective design, using carefully selected validated instruments, to measure the prevalence and severity of genitourinary symptoms In postmenopausal women with breast cancer (prior to adjuvant endocrine therapy) and documented the trajectory of symptoms over time. The Impact of genitourinary symptoms on sexual function and QoL was also Investigated. The study attempted to Identify predictors for which women were more likely to develop significant genitourinary symptoms, and In particular, whether there Is an Identifiable sub-group of women at high-risk of developing severe genitourinary symptoms. This research project was conducted In the hope that the findings would Inform clinical practice and lead to greater efforta to early recognition and appropriate management of postmenopausal women who develop significant genitourinary symptoms as a result of adjuvant endocrine therapy. Declaration relating to disposition of project thesis/dissertation I hereby grant to the University of New South Wales or its agents the right to archive and to make available my thesis or dissertation in whole or in part in the University libraries in all forms of media, now or here after known, subject to the provisions of the Copyright Act 1968. I retain all property rights, such as patent rights. I also retain the right to use in future works (such as articles or books) all or part of this thesis or dissertation . I also authorise University Micr films to use the 350 word abstract of my thesis in Dissertation Abstracts International (this is applicable to doctoral theses only) 1 ~.,.:_. ~ . J,.~ .. m. 16-o::!C The University recognises that there may be exceptional circumstances requiring restrictions on copying or cond ~ions on use. Requests for restriction for a period of up to 2 years must be made in writing. Requests for a longer period of restriction may be considered in exceptional circumstances and require the approval of the Dean of Graduate Research . FOR OFFICE USE DNLY Date of completion of requirements for Award: THIS SHEET IS TO BE GLUED TO THE INSIDE FRONT COVER OF THE THESIS ii iv “Often I think women who had breast cancer have very little opportunity to talk to people and a lot of the issues are very shaming so it is really important to offer them that chance.” ― Memorable quote from one of the participants in this research project [GT, Post, 06] v vi ABSTRACT The underlying hypothesis of this PhD is that the negative impact of adjuvant endocrine therapy on genitourinary symptoms in postmenopausal women with early breast cancer has been underestimated in clinical trials and that there are a myriad of genitourinary symptoms related to or exacerbated by endocrine therapies that are commonly not reported by women to their oncologists. These symptoms can be troublesome and may lead to noncompliance with treatment, especially if associated with other side effects. This issue has not been comprehensively addressed, resulting in uncertainty regarding the frequency and severity of genitourinary adverse effects associated with antiestrogens and their potential impact on quality of life (QoL). Furthermore, no studies have comprehensively and prospectively evaluated the full range of genitourinary symptoms from before therapy begins and over time. These symptoms include urinary frequency, urgency, incontinence, dysuria, prolapse among others. This study fills an important gap in the current literature and is clinically important as interventions could be used to better manage and treat many of these symptoms. A number of data collection methods and instruments were used in this project, selected on their ability to address the proposed research questions. Using a qualitative approach, with semi- structured interviews, Study I sought an in-depth insight of the genitourinary symptoms experienced by women with early breast cancer on antiestrogen therapy and an understanding on how symptoms impact on daily life and sexual function. Study II employed a prospective design, using carefully selected validated instruments, to measure the prevalence and severity of genitourinary symptoms in postmenopausal women with breast cancer (prior to adjuvant endocrine therapy) and documented the trajectory of symptoms over time. The impact of genitourinary symptoms on sexual function and QoL was also investigated. The study attempted to identify predictors for which women were more likely to develop significant genitourinary symptoms, and in particular, whether there is an identifiable sub-group of women at high-risk of developing severe genitourinary symptoms. This research project was conducted in the hope that the findings would inform clinical practice and lead to greater efforts to early recognition and appropriate management of postmenopausal women who develop significant genitourinary symptoms as a result of adjuvant endocrine therapy. vii viii ACKNOWLEDGEMENTS I have a lot of people to thank for their continued support and love over the past three years. Firstly I would like to acknowledge the brave and courageous women who were willing to give their time and share their very personal experiences with breast cancer and the impact on their lives. Your words and stories are illuminating and the experience has been humbling. Next I need to express my gratitude to Prof. Michael Friedlander, my supervisor, for mentoring me through this journey of research. Thank you for allowing me to stay close to my area of interest and your encouraging guidance throughout the process, especially when I thought I had no more strength to ‘hang in there’. Prof. Martha Hickey, thank you for sharing your deep knowledge and helping me to navigate the world of women’s needs. I would like to especially thank Dr Michelle Peate for guiding me through each and every step of this thesis, all the countless hours of technical and moral support, motivating and inspiring me. You are an encouraging and invaluable friend. I would like to acknowledge the support of the Breast Cancer Network Australia (BCNA) Consumer Representative, Ms Yvonne Shaw, for so much meaningful advice and input in this project. I would like to also thank Ms Sherin Jarvis, A/Prof. Craig Lewis, Dr. Marcus Carey and Prof. Richard Millard for the expertise that they contributed. On a more personal note, I would like to thank my parents, Miratan and Thais, for being so supportive of my career and giving me the will to chase my ambitions. I know that you are proud of me and that means so much. Thank you to my sister, Camila, you helped me reach my goal still smiling. One year ago, you and Ryan gave me the perfect gift, my little nephew William, who have brought
Recommended publications
  • Identification of Chalcone Derivatives As Putative Non-Steroidal Aromatase
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Online Publishing @ NISCAIR Indian Journal of Chemistry Vol. 59B, February 2020, pp. 283-293 Identification of chalcone derivatives as putative non-steroidal aromatase inhibitors potentially useful against breast cancer by molecular docking and ADME prediction Umang Shah*a, Samir Patela, Mehul Patela, Karan Gandhia & Ashish Patelb a Department of Pharmaceutical Chemistry, Ramanbhai Patel College of Pharmacy, Charotar University of Science and Technology, Changa 388 421, India b Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Parul University, P.O. Limda 391 760, Dist. Vadodara, India E-mail: [email protected] Received 30 August 2019; accepted (revised) 16 October 2019 Aromatase is an influential target to overcome estrogen receptor positive breast cancer, as the enzyme is responsible for conversion of androstenedione to estrone, a promising drug target for therapeutic management of breast cancer. Chalcones are prominent biosynthetic compounds and parent candidate for the synthesis of heterocycles with diversified biological activities. The prime objective of the present study is to evaluate the binding interaction of 2-hydroxyphenyl- prop-2-en-1- one (1A-1X), 2-hydroxy-4-methoxyphenyl- prop-2-en-1-one (3A-3X), 2,4-dihydroxyphenyl- prop-2-en-1-one (9A-9X) and 1-hydroxynaphthalen-2-yl-prop-2-en-1-one (5A-5X) derivatives with aromatase enzyme by molecular docking study and also check their ADME properties by maestro suit. The designed chalcones derivatives have been docked against our target protein with PDB id 3S7S retrieved from the protein data bank, whereas exemestane has been taken as the positive control.
    [Show full text]
  • NINDS Custom Collection II
    ACACETIN ACEBUTOLOL HYDROCHLORIDE ACECLIDINE HYDROCHLORIDE ACEMETACIN ACETAMINOPHEN ACETAMINOSALOL ACETANILIDE ACETARSOL ACETAZOLAMIDE ACETOHYDROXAMIC ACID ACETRIAZOIC ACID ACETYL TYROSINE ETHYL ESTER ACETYLCARNITINE ACETYLCHOLINE ACETYLCYSTEINE ACETYLGLUCOSAMINE ACETYLGLUTAMIC ACID ACETYL-L-LEUCINE ACETYLPHENYLALANINE ACETYLSEROTONIN ACETYLTRYPTOPHAN ACEXAMIC ACID ACIVICIN ACLACINOMYCIN A1 ACONITINE ACRIFLAVINIUM HYDROCHLORIDE ACRISORCIN ACTINONIN ACYCLOVIR ADENOSINE PHOSPHATE ADENOSINE ADRENALINE BITARTRATE AESCULIN AJMALINE AKLAVINE HYDROCHLORIDE ALANYL-dl-LEUCINE ALANYL-dl-PHENYLALANINE ALAPROCLATE ALBENDAZOLE ALBUTEROL ALEXIDINE HYDROCHLORIDE ALLANTOIN ALLOPURINOL ALMOTRIPTAN ALOIN ALPRENOLOL ALTRETAMINE ALVERINE CITRATE AMANTADINE HYDROCHLORIDE AMBROXOL HYDROCHLORIDE AMCINONIDE AMIKACIN SULFATE AMILORIDE HYDROCHLORIDE 3-AMINOBENZAMIDE gamma-AMINOBUTYRIC ACID AMINOCAPROIC ACID N- (2-AMINOETHYL)-4-CHLOROBENZAMIDE (RO-16-6491) AMINOGLUTETHIMIDE AMINOHIPPURIC ACID AMINOHYDROXYBUTYRIC ACID AMINOLEVULINIC ACID HYDROCHLORIDE AMINOPHENAZONE 3-AMINOPROPANESULPHONIC ACID AMINOPYRIDINE 9-AMINO-1,2,3,4-TETRAHYDROACRIDINE HYDROCHLORIDE AMINOTHIAZOLE AMIODARONE HYDROCHLORIDE AMIPRILOSE AMITRIPTYLINE HYDROCHLORIDE AMLODIPINE BESYLATE AMODIAQUINE DIHYDROCHLORIDE AMOXEPINE AMOXICILLIN AMPICILLIN SODIUM AMPROLIUM AMRINONE AMYGDALIN ANABASAMINE HYDROCHLORIDE ANABASINE HYDROCHLORIDE ANCITABINE HYDROCHLORIDE ANDROSTERONE SODIUM SULFATE ANIRACETAM ANISINDIONE ANISODAMINE ANISOMYCIN ANTAZOLINE PHOSPHATE ANTHRALIN ANTIMYCIN A (A1 shown) ANTIPYRINE APHYLLIC
    [Show full text]
  • Us Anti-Doping Agency
    2019U.S. ANTI-DOPING AGENCY WALLET CARDEXAMPLES OF PROHIBITED AND PERMITTED SUBSTANCES AND METHODS Effective Jan. 1 – Dec. 31, 2019 CATEGORIES OF SUBSTANCES PROHIBITED AT ALL TIMES (IN AND OUT-OF-COMPETITION) • Non-Approved Substances: investigational drugs and pharmaceuticals with no approval by a governmental regulatory health authority for human therapeutic use. • Anabolic Agents: androstenediol, androstenedione, bolasterone, boldenone, clenbuterol, danazol, desoxymethyltestosterone (madol), dehydrochlormethyltestosterone (DHCMT), Prasterone (dehydroepiandrosterone, DHEA , Intrarosa) and its prohormones, drostanolone, epitestosterone, methasterone, methyl-1-testosterone, methyltestosterone (Covaryx, EEMT, Est Estrogens-methyltest DS, Methitest), nandrolone, oxandrolone, prostanozol, Selective Androgen Receptor Modulators (enobosarm, (ostarine, MK-2866), andarine, LGD-4033, RAD-140). stanozolol, testosterone and its metabolites or isomers (Androgel), THG, tibolone, trenbolone, zeranol, zilpaterol, and similar substances. • Beta-2 Agonists: All selective and non-selective beta-2 agonists, including all optical isomers, are prohibited. Most inhaled beta-2 agonists are prohibited, including arformoterol (Brovana), fenoterol, higenamine (norcoclaurine, Tinospora crispa), indacaterol (Arcapta), levalbuterol (Xopenex), metaproternol (Alupent), orciprenaline, olodaterol (Striverdi), pirbuterol (Maxair), terbutaline (Brethaire), vilanterol (Breo). The only exceptions are albuterol, formoterol, and salmeterol by a metered-dose inhaler when used
    [Show full text]
  • Part I Biopharmaceuticals
    1 Part I Biopharmaceuticals Translational Medicine: Molecular Pharmacology and Drug Discovery First Edition. Edited by Robert A. Meyers. © 2018 Wiley-VCH Verlag GmbH & Co. KGaA. Published 2018 by Wiley-VCH Verlag GmbH & Co. KGaA. 3 1 Analogs and Antagonists of Male Sex Hormones Robert W. Brueggemeier The Ohio State University, Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, Columbus, Ohio 43210, USA 1Introduction6 2 Historical 6 3 Endogenous Male Sex Hormones 7 3.1 Occurrence and Physiological Roles 7 3.2 Biosynthesis 8 3.3 Absorption and Distribution 12 3.4 Metabolism 13 3.4.1 Reductive Metabolism 14 3.4.2 Oxidative Metabolism 17 3.5 Mechanism of Action 19 4 Synthetic Androgens 24 4.1 Current Drugs on the Market 24 4.2 Therapeutic Uses and Bioassays 25 4.3 Structure–Activity Relationships for Steroidal Androgens 26 4.3.1 Early Modifications 26 4.3.2 Methylated Derivatives 26 4.3.3 Ester Derivatives 27 4.3.4 Halo Derivatives 27 4.3.5 Other Androgen Derivatives 28 4.3.6 Summary of Structure–Activity Relationships of Steroidal Androgens 28 4.4 Nonsteroidal Androgens, Selective Androgen Receptor Modulators (SARMs) 30 4.5 Absorption, Distribution, and Metabolism 31 4.6 Toxicities 32 Translational Medicine: Molecular Pharmacology and Drug Discovery First Edition. Edited by Robert A. Meyers. © 2018 Wiley-VCH Verlag GmbH & Co. KGaA. Published 2018 by Wiley-VCH Verlag GmbH & Co. KGaA. 4 Analogs and Antagonists of Male Sex Hormones 5 Anabolic Agents 32 5.1 Current Drugs on the Market 32 5.2 Therapeutic Uses and Bioassays
    [Show full text]
  • Tanibirumab (CUI C3490677) Add to Cart
    5/17/2018 NCI Metathesaurus Contains Exact Match Begins With Name Code Property Relationship Source ALL Advanced Search NCIm Version: 201706 Version 2.8 (using LexEVS 6.5) Home | NCIt Hierarchy | Sources | Help Suggest changes to this concept Tanibirumab (CUI C3490677) Add to Cart Table of Contents Terms & Properties Synonym Details Relationships By Source Terms & Properties Concept Unique Identifier (CUI): C3490677 NCI Thesaurus Code: C102877 (see NCI Thesaurus info) Semantic Type: Immunologic Factor Semantic Type: Amino Acid, Peptide, or Protein Semantic Type: Pharmacologic Substance NCIt Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor tyrosine kinase expressed by endothelial cells, while VEGF is overexpressed in many tumors and is correlated to tumor progression. PDQ Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor
    [Show full text]
  • Drug Name Plate Number Well Location % Inhibition, Screen Axitinib 1 1 20 Gefitinib (ZD1839) 1 2 70 Sorafenib Tosylate 1 3 21 Cr
    Drug Name Plate Number Well Location % Inhibition, Screen Axitinib 1 1 20 Gefitinib (ZD1839) 1 2 70 Sorafenib Tosylate 1 3 21 Crizotinib (PF-02341066) 1 4 55 Docetaxel 1 5 98 Anastrozole 1 6 25 Cladribine 1 7 23 Methotrexate 1 8 -187 Letrozole 1 9 65 Entecavir Hydrate 1 10 48 Roxadustat (FG-4592) 1 11 19 Imatinib Mesylate (STI571) 1 12 0 Sunitinib Malate 1 13 34 Vismodegib (GDC-0449) 1 14 64 Paclitaxel 1 15 89 Aprepitant 1 16 94 Decitabine 1 17 -79 Bendamustine HCl 1 18 19 Temozolomide 1 19 -111 Nepafenac 1 20 24 Nintedanib (BIBF 1120) 1 21 -43 Lapatinib (GW-572016) Ditosylate 1 22 88 Temsirolimus (CCI-779, NSC 683864) 1 23 96 Belinostat (PXD101) 1 24 46 Capecitabine 1 25 19 Bicalutamide 1 26 83 Dutasteride 1 27 68 Epirubicin HCl 1 28 -59 Tamoxifen 1 29 30 Rufinamide 1 30 96 Afatinib (BIBW2992) 1 31 -54 Lenalidomide (CC-5013) 1 32 19 Vorinostat (SAHA, MK0683) 1 33 38 Rucaparib (AG-014699,PF-01367338) phosphate1 34 14 Lenvatinib (E7080) 1 35 80 Fulvestrant 1 36 76 Melatonin 1 37 15 Etoposide 1 38 -69 Vincristine sulfate 1 39 61 Posaconazole 1 40 97 Bortezomib (PS-341) 1 41 71 Panobinostat (LBH589) 1 42 41 Entinostat (MS-275) 1 43 26 Cabozantinib (XL184, BMS-907351) 1 44 79 Valproic acid sodium salt (Sodium valproate) 1 45 7 Raltitrexed 1 46 39 Bisoprolol fumarate 1 47 -23 Raloxifene HCl 1 48 97 Agomelatine 1 49 35 Prasugrel 1 50 -24 Bosutinib (SKI-606) 1 51 85 Nilotinib (AMN-107) 1 52 99 Enzastaurin (LY317615) 1 53 -12 Everolimus (RAD001) 1 54 94 Regorafenib (BAY 73-4506) 1 55 24 Thalidomide 1 56 40 Tivozanib (AV-951) 1 57 86 Fludarabine
    [Show full text]
  • Confidential: for Review Only
    BMJ Confidential: For Review Only The risk of fall and fracture with the initiation of a prostate - selective alpha antagonist Journal: BMJ Manuscript ID: BMJ.2015.028205 Article Type: Research BMJ Journal: BMJ Date Submitted by the Author: 17-Jul-2015 Complete List of Authors: Welk, Blayne; Western University, McArthur, Eric; Institute for Clinical Evaluative Sciences,, Fraser, Lisa-Ann; Western University, Medicine Hayward, Jade; Institute for Clinical Evaluative Sciences,, Dixon, Stephanie; Institute for Clinical Evaluative Sciences,, Hwang, Joseph; Case Western Reserve University School of Medicine, Ordon, Michael; University of Toronto, Surgery (Urology) Keywords: BPH, Fall, Fracture, Alpha antgonist https://mc.manuscriptcentral.com/bmj Page 1 of 45 BMJ 1 2 The risk of fall and fracture with the initiation of a prostate-selective alpha antagonist 3 4 1,2,3 2 4 2 5 Blayne Welk MD MSc , Eric McArthur MSc , Lisa-Ann Fraser MD MSc , Jade Hayward , 6 Stephanie Dixon MSc PhD 2,3 , Y. Joseph Hwang MSc 5, Michael Ordon MD MSc 6 7 8 1 DepartmentConfidential: of Surgery, Western University, For London Review, Ontario, Canada Only 9 2 Institute for Clinical Evaluative Sciences, London, Ontario, Canada 10 11 3 Department of Epidemiology and Biostatistics, Western University, London, Ontario, Canada 12 4 Department of Medicine, Western University, London, Ontario 13 5 MD Candidate, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA 14 6 Division of Urology, Department of Surgery, University of Toronto, Toronto, Ontario, Canada 15 16 17 Correspondence: 18 Blayne Welk, MD MSc 19 Assistant Professor, Division of Urology and Epidemiology and Biostatistics 20 Western University 21 Room B4-667 22 23 St Joseph's Health Care 24 268 Grosvenor Street London ON N6A 4V2 25 Telephone: 519 646-6367 | Fax: 519 646-6037 26 [email protected] 27 28 29 Addresses: 30 Mr McArthur: [email protected] 31 LHSC – Victoria Hospital 32 ELL-101, 800 Commissioners Rd.
    [Show full text]
  • Differences Between the Non-Steroidal Aromatase Inhibitors Anastrozole and Letrozole – of Clinical Importance?
    British Journal of Cancer (2011) 104, 1059 – 1066 & 2011 Cancer Research UK All rights reserved 0007 – 0920/11 www.bjcancer.com Minireview Differences between the non-steroidal aromatase inhibitors anastrozole and letrozole – of clinical importance? ,1 J Geisler* 1 Institute of Clinical Medicine, University of Oslo, Faculty Division at Akershus University Hospital, Sykehusveien 27, Lørenskog N-1478, Norway Aromatase inhibition is the gold standard for treatment of early and advanced breast cancer in postmenopausal women suffering from an estrogen receptor-positive disease. The currently established group of anti-aromatase compounds comprises two reversible aromatase inhibitors (anastrozole and letrozole) and on the other hand, the irreversible aromatase inactivator exemestane. Although exemestane is the only widely used aromatase inactivator at this stage, physicians very often have to choose between either anastrozole or letrozole in general practice. These third-generation aromatase inhibitors (letrozole/Femara (Novartis Pharmaceuticals, Basel, Switzerland) and anastrozole/Arimidex (AstraZeneca, Pharmaceuticals, Macclesfield, Cheshire, UK)), have recently demonstrated superior efficacy compared with tamoxifen as initial therapy for early breast cancer improving disease-free survival. However, although anastrozole and letrozole belong to the same pharmacological class of agents (triazoles), an increasing body of evidence suggests that these aromatase inhibitors are not equipotent when given in the clinically established doses. Preclinical and clinical evidence indicates distinct pharmacological profiles. Thus, this review focuses on the differences between the non-steroidal aromatase inhibitors allowing physicians to choose between these compounds based on scientific evidence. Although we are waiting for the important results of a still ongoing head-to-head comparison in patients with early breast cancer at high risk for relapse (Femara Anastrozole Clinical Evaluation trial; ‘FACE-trial’), clinicians have to make their choices today.
    [Show full text]
  • WO 2017/112768 Al 29 June 2017 (29.06.2017) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2017/112768 Al 29 June 2017 (29.06.2017) P O P C T (51) International Patent Classification: Delaware 19707 (US). ZHUANG, Linghang; 3135 Fox C07D 471/10 (2006.01) A61K 31/47 (2006.01) Drive, Chalfont, Pennsylvania 18914 (US). C07D 487/10 (2006.01) A61K 31/519 (2006.01) (74) Agents: DAVEY, PH.D., Evan A. et al; Fish & Richard C07D 495/04 (2006.01) A61P 35/02 (2006.01) son P.C., P.O. Box 1022, Minneapolis, Minnesota 55440- C07D 513/04 (2006.01) 1022 (US). (21) International Application Number: (81) Designated States (unless otherwise indicated, for every PCT/US20 16/0680 16 kind of national protection available): AE, AG, AL, AM, (22) International Filing Date: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, 2 1 December 2016 (21 .12.2016) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (25) Filing Language: English HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, (26) Publication Language: English KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, (30) Priority Data: NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, 62/270,973 22 December 201 5 (22. 12.2015) US RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, (71) Applicant: VITAE PHARMACEUTICALS, INC.
    [Show full text]
  • Aromatase and Its Inhibitors: Significance for Breast Cancer Therapy † EVAN R
    Aromatase and Its Inhibitors: Significance for Breast Cancer Therapy † EVAN R. SIMPSON* AND MITCH DOWSETT *Prince Henry’s Institute of Medical Research, Monash Medical Centre, Clayton, Victoria 3168, Australia; †Department of Biochemistry, Royal Marsden Hospital, London SW3 6JJ, United Kingdom ABSTRACT Endocrine adjuvant therapy for breast cancer in recent years has focussed primarily on the use of tamoxifen to inhibit the action of estrogen in the breast. The use of aromatase inhibitors has found much less favor due to poor efficacy and unsustainable side effects. Now, however, the situation is changing rapidly with the introduction of the so-called phase III inhibitors, which display high affinity and specificity towards aromatase. These compounds have been tested in a number of clinical settings and, almost without exception, are proving to be more effective than tamoxifen. They are being approved as first-line therapy for elderly women with advanced disease. In the future, they may well be used not only to treat young, postmenopausal women with early-onset disease but also in the chemoprevention setting. However, since these compounds inhibit the catalytic activity of aromatase, in principle, they will inhibit estrogen biosynthesis in every tissue location of aromatase, leading to fears of bone loss and possibly loss of cognitive function in these younger women. The concept of tissue-specific inhibition of aromatase expression is made possible by the fact that, in postmenopausal women when the ovaries cease to produce estrogen, estrogen functions primarily as a local paracrine and intracrine factor. Furthermore, due to the unique organization of tissue-specific promoters, regulation in each tissue site of expression is controlled by a unique set of regulatory factors.
    [Show full text]
  • Periodic Hypokalaemic Paralysis, Adrenal Adenoma, and Normal Colonic Transport of Sodium and Potassium
    Gut: first published as 10.1136/gut.14.6.478 on 1 June 1973. Downloaded from Gut, 1973, 14, 478-484 Periodic hypokalaemic paralysis, adrenal adenoma, and normal colonic transport of sodium and potassium PETER RICHARDS1, M. B. S. JONES, AND W. S. PEART From the Medical Unit, St Mary's Hospital Medical School, London SUMMARY A 47-year-old woman was cured of hypokalaemia and recurrent paralysis by the excision of an adrenal adenoma. Hypertension was initially ameliorated but was not cured. Suppression of plasma renin activity was abolished when the adenoma was excised. Repeated measurement of plasma corticosteroids before operation showed a slight increase in aldosterone and normal plasma concentrations of deoxycorticosterone, corticosterone, and cortisol. No evidence of excess mineralo- corticoid was obtained from measurement of the electrolyte composition of colonic fluid or of rectal potential difference, although both these variables responded normally to salt depletion and exogenous aldosterone. The diagnostic importance of the paradoxically normal colonic measure- ments is emphasized and the possibility is considered that the adenoma may have secreted an unidentified hormone. http://gut.bmj.com/ The colon normally responds to excessive plasma not escape from the action of these hormones. One concentrations of aldosterone, corticosterone, and patient has been described in whom colonic sodium deoxycorticosterone by modifying faecal fluid so fluxes were apparently normal and were unchanged that the concentration of sodium is very low and that by the excision of an aldosterone-secreting adrenal of potassium high (Wrong, Morrison, and Hurst, adenoma; potassium influx was nevertheless in- 1961; Wrong and Metcalfe-Gibson, 1965; creased and returned to normal after operation Richards, on September 29, 2021 by guest.
    [Show full text]
  • Pharmacology/Therapeutics II Block III Lectures 2013-14
    Pharmacology/Therapeutics II Block III Lectures 2013‐14 66. Hypothalamic/pituitary Hormones ‐ Rana 67. Estrogens and Progesterone I ‐ Rana 68. Estrogens and Progesterone II ‐ Rana 69. Androgens ‐ Rana 70. Thyroid/Anti‐Thyroid Drugs – Patel 71. Calcium Metabolism – Patel 72. Adrenocorticosterioids and Antagonists – Clipstone 73. Diabetes Drugs I – Clipstone 74. Diabetes Drugs II ‐ Clipstone Pharmacology & Therapeutics Neuroendocrine Pharmacology: Hypothalamic and Pituitary Hormones, March 20, 2014 Lecture Ajay Rana, Ph.D. Neuroendocrine Pharmacology: Hypothalamic and Pituitary Hormones Date: Thursday, March 20, 2014-8:30 AM Reading Assignment: Katzung, Chapter 37 Key Concepts and Learning Objectives To review the physiology of neuroendocrine regulation To discuss the use neuroendocrine agents for the treatment of representative neuroendocrine disorders: growth hormone deficiency/excess, infertility, hyperprolactinemia Drugs discussed Growth Hormone Deficiency: . Recombinant hGH . Synthetic GHRH, Recombinant IGF-1 Growth Hormone Excess: . Somatostatin analogue . GH receptor antagonist . Dopamine receptor agonist Infertility and other endocrine related disorders: . Human menopausal and recombinant gonadotropins . GnRH agonists as activators . GnRH agonists as inhibitors . GnRH receptor antagonists Hyperprolactinemia: . Dopamine receptor agonists 1 Pharmacology & Therapeutics Neuroendocrine Pharmacology: Hypothalamic and Pituitary Hormones, March 20, 2014 Lecture Ajay Rana, Ph.D. 1. Overview of Neuroendocrine Systems The neuroendocrine
    [Show full text]